Overview

Price chart · mood · technical indicators

CUE

Cue Biopharmastock Healthcare

Biotechnology

$29.8532.63%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$4.97$38.00

Current: $29.85

Market Comparison

vs Healthcare Sector & Biotechnology Industry

CUE

+32.63%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-8.400.0% YoY

Profit margin-96.9%HEALTHCARE

Market cap$99.0MMicro cap

Wall Street coverage

$115.00median target· current $62.40 (+84.3%)1 analyst

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 3.74
P/S (TTM): 3.61
EV/EBITDA: -1.76

Profitability & growth

ROE (TTM): -121.1%
Operating margin: 8.9%
Revenue growth YoY: 1292.0%
Dividend yield: —
Beta: 1.58

Last earnings

Mar 24, 2026 · Estimate $-0.09 · Reported $0.01

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Cue Biopharma

Company profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 40 GUEST STREET, BOSTON, MA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$99.0M

Shares outstanding$3.3M

52W high$38.00

52W low$4.97

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

CUE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen

Cue Biopharma Raises $30 Million in Private Placement to Advance Immunology Pipeline

Cue Biopharma, Inc. Trade Ideas — SWB:1UC0

Cue Biopharma (CUE) Secures $30M in Private Placement Financing

Cue Biopharma Secures $30 Million Financing and New CEO

Cue Biopharma licenses anti-IgE antibody for allergic diseases

Cue Biopharma appoints Shao-Lee Lin as CEO and president By Investing.com

Cue Biopharma lines up $30M to fund pipeline and Ascendant-221

Cue pays $15M for allergy drug, targets food allergy trial

Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma, Inc. Revenue Breakdown – SWB:1UC0

Current ratio of Cue Biopharma, Inc. – SWB:1UC0

CUE - Cue Biopharma Inc Stock Price and Quote

Cue Biopharma, Inc. Income Statement – GETTEX:1UC0

Cue Biopharma, Inc. Cash Flow – GETTEX:1UC0

Equity in earnings of Cue Biopharma, Inc. – LSX:A426PN

Equity in earnings of Cue Biopharma, Inc. – GETTEX:1UC0

Cue Biopharma, Inc. Cash Flow – LSX:A426PN

About Cue Biopharma

Classification

Company profile

CUE

Market Comparison

CUE Market Analysis

Overview

CUE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Cue Biopharma (NASDAQ:CUE) Downgraded to Buy Rating by Wall Street Zen

Cue Biopharma Raises $30 Million in Private Placement to Advance Immunology Pipeline

Cue Biopharma, Inc. Trade Ideas — SWB:1UC0

Cue Biopharma (CUE) Secures $30M in Private Placement Financing

Cue Biopharma Secures $30 Million Financing and New CEO

Cue Biopharma licenses anti-IgE antibody for allergic diseases

Cue Biopharma appoints Shao-Lee Lin as CEO and president By Investing.com

Cue Biopharma lines up $30M to fund pipeline and Ascendant-221

Cue pays $15M for allergy drug, targets food allergy trial

Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Cue Biopharma, Inc. Revenue Breakdown – SWB:1UC0

Current ratio of Cue Biopharma, Inc. – SWB:1UC0

CUE - Cue Biopharma Inc Stock Price and Quote

Cue Biopharma, Inc. Income Statement – GETTEX:1UC0

Cue Biopharma, Inc. Cash Flow – GETTEX:1UC0

Equity in earnings of Cue Biopharma, Inc. – LSX:A426PN

Equity in earnings of Cue Biopharma, Inc. – GETTEX:1UC0

Cue Biopharma, Inc. Cash Flow – LSX:A426PN

About Cue Biopharma

Classification

Company profile

CUE

Market Comparison